Literature DB >> 2410111

Isoprinosine and Imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms.

A Pompidou, M C Delsaux, L Telvi, B Mace, F Coutance, A Falkenrodt, J M Lang.   

Abstract

Isoprinosine and Imuthiol are immunomodulators with a unique effect on T-cells. The possibility of using them in treating patients with acquired immunodeficiency syndrome related complex (ARC) was initially examined regarding their in vitro effects on peripheral blood mononuclear cells. In six ARC patients Isoprinosine (100 micrograms/ml) and Imuthiol (10 pg/ml) induced in vitro an early chromatin activation as measured by nuclear refringency test and potentiated phytohemagglutinin (5 micrograms/ml) in the same 20-min assay in the absence of fetal calf serum. In all patients an early phytohemagglutinin induced chromatin dispersion was observed with a dose related response before interleukin 2 production can occur. Isoprinosine and Imuthiol increased significantly both the percentage and the absolute number of T4+ cells when peripheral blood mononuclear cells were incubated for 4 days in RPMI supplemented with 10% fetal calf serum. No changes in T8+ cells were noted. Three homosexual ARC patients were then treated p.o. with Imuthiol (5-10 mg/kg/week) for 4 to 6 months. Without any deleterious effect a clinical improvement (in terms of adenopathy and opportunistic infection regression) and restoration of the response to recall antigens were observed in all three patients. One patient with less than 500 T4+ lymphocytes/mm3 exhibited a complete restoration of OKT profiles. In such patients clinical and immunological effects of Isoprinosine have already been reported by others. Altogether these preliminary results indicate that more data should be obtained on the effects of these two agents in ARC patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410111

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  Treatment of the acquired immune deficiency syndrome.

Authors:  S Gupta; M S Gottlieb
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

Review 3.  Sulphane sulphur in biological systems: a possible regulatory role.

Authors:  J I Toohey
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

4.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 5.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 6.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 7.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

8.  Viral infections in the acquired immunodeficiency syndrome.

Authors:  S E Miller; D N Howell
Journal:  J Electron Microsc Tech       Date:  1988-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.